



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	10/607,175	
	Filing Date	June 26, 2003	
	First Named Inventor	White, et al.	
	Art Unit	1645	
	Examiner Name	Unknown	
Total Number of Pages in This Submission	9	Attorney Docket Number	1145-222

**ENCLOSURES** (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Cited references, return postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual name	FRELING E. BAKER
Signature	<i>Freling E. Baker</i>
Date	OCTOBER 31, 2003

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Beverly Erdman		
Signature	<i>Beverly Erdman</i>	Date	10/31/2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of:	)	
	)	
White et al	)	Art Unit: 1645
	)	
Serial No.: 10/607,175	)	
	)	Examiner: (Unknown)
	)	
Filed: June 26, 2003	)	Atty. Docket No.: 1145-222
	)	
For: METHOD AND BUILDING	)	
BLOCKS FOR PREPARING	)	
C-TERMINALLY LABELED	)	
PEPTIDES,	)	

Mail Stop IDS  
Commissioner for Patents  
P.O Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**


Applicant hereby discloses the documents listed in accompanying Form PTO-1449 with respect to the above-referenced patent application under the provisions of 37 C.F.R., Sections 1.56, 1.97 and 1.98.

The filing of this Information Disclosure Statement should not be construed to mean that a search was conducted or that no other material information, as defined by 37 C.F.R. 1.56, exists.

It is Applicant's opinion that the essential features of the invention are neither described in nor obvious from any of the references mentioned above, whether taken individually or in any reasonable combination.

The Examiner is respectfully requested to make the listed documents of record in connection with the prosecution of the subjection application.

Respectfully submitted,



Freling E. Baker


October 31, 2003  
Freling E. Baker  
Brown Martin Haller & McClain LLP  
1660 Union Street  
San Diego, California 92130

Telephone: (619) 238-0999  
Fax: (619) 238-0062

Form PTO-1449

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**

(Use Several Sheets If Necessary)



Docket No.: 1145-222

Application No. : 10/607,175

Applicant: White et al

Filing Date: June 26, 2003

Group Art Unit: 1645

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
							X

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

		Kumar et al, Organic Letters, Vol. 5, No. 5, 613-616 (2003) " A Solid- Phase Synthetic Strategy for Labeled Peptides: Synthesis of a Biotinylated Derivative of the $\delta$ Opioid Receptor Antagonist TIPP (Tyr-Tic-Phe-Phe-OH).
		Sebestik et al , abstract entitled " L13- Ability of bis-intercalators peptide libraries functionalized with 9-amino acridine to block an aggregation of HuPrP106-126 (difficult sequence) in the presence of gc-rich DNA" presented at the European Peptide Symposium commencing on August 31, 2002 .
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not considered. Include copy of this form with next communication to the applicant. (2/92 PTO)